Discovery of novel KRAS‒PDEδ inhibitors with potent activity in patient-derived human pancreatic tumor xenograft models

KRAS‒PDEδ interaction is revealed as a promising target for suppressing the function of mutant KRAS. The bottleneck in clinical development of PDEδ inhibitors is the poor antitumor activity of known chemotypes. Here, we identified novel spiro-cyclic PDEδ inhibitors with potent antitumor activity bot...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Long, Zhang, Jing, Wang, Xinjing, Li, Yu, Zhou, Lu, Lu, Xiongxiong, Dong, Guoqiang, Sheng, Chunquan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799878/
https://www.ncbi.nlm.nih.gov/pubmed/35127385
http://dx.doi.org/10.1016/j.apsb.2021.07.009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799878/
https://www.ncbi.nlm.nih.gov/pubmed/35127385
http://dx.doi.org/10.1016/j.apsb.2021.07.009

Ejemplares similares